We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
UK-based company Genomics has entered a collaborative deal with US-based biotechnology firm Biogen to discover new treatments for multiple sclerosis (MS).
Researchers from the Universities of Exeter and Alberta have identified a protein in the brain which they believe could be key in the onset of multiple sclerosis.